Cromos Pharma is delighted to be participating again this year at the 62nd ASH Annual Meeting & Exposition 5-8 December, 2020, the premier event for malignant and non-malignant hematology.
Extensive expertise in hematology-oncology
Cromos Pharma has extensive experience in managing all aspects of clinical trials in hematology-oncology in all Phases, I, II, III and post market/observational. Oncology studies represent nearly 20% of our work and we have successfully managed 20+ studies in hematology-oncology. Regulatory inspections and site audits attest to the highest quality of our clinical data: EMA in 2019 (1-week oncology site inspection); FDA in 2017 (2-week oncology site inspection).
We have global expertise combined with in-depth experience and knowledge in Central and Eastern Europe. We have an extensive PI/site network and unparalleled access to patient databases and key opinion leaders. These relationships have helped us achieve an unrivalled record for patient recruitment – our team has met or reduced enrollment timelines in 95% of trials conducted over our sixteen year history. Responsible recruitment is supported by our “No Patients-No Payments” initiative – a unique risk-sharing program.
Our expert team also offers the most optimized start-up timelines in these regions. For example, we routinely achieve regulatory approvals in the Republic of Georgia, within two months of project signing (In Russia, 4 months, and in Ukraine, less than 5 months).